• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Why Fortrea (FTRE) Stock Is Up Today

By: StockStory
October 08, 2025 at 13:45 PM EDT

FTRE Cover Image

What Happened?

Shares of clinical research company Fortrea Holdings (NASDAQ: FTRE) jumped 6.1% in the afternoon session after Evercore ISI Group raised its price target on the company to $11.00 from a previous $7.00. 

The firm maintained its 'In-Line' rating, which typically means the stock is expected to perform similarly to its industry peers. This adjustment by analyst Elizabeth Anderson represented a significant increase of over 57%. While the rating itself was not an upgrade, the substantial price target revision suggested a more positive outlook on the company's future stock performance from the analyst firm.

Is now the time to buy Fortrea? Access our full analysis report here.

What Is The Market Telling Us

Fortrea’s shares are extremely volatile and have had 65 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 13 days ago when the stock dropped 6.3% as negative news weighed on the broader healthcare sector, including a new U.S. government investigation into medical equipment imports and a report detailing potential revenue losses from expiring tax credits. The U.S. Commerce Department initiated an investigation into the national security implications of importing a wide range of healthcare products, from surgical masks to pacemakers. This review raised the possibility of future tariffs or quotas on these goods.

Fortrea is down 47.1% since the beginning of the year, and at $9.87 per share, it is trading 58.4% below its 52-week high of $23.73 from December 2024. Investors who bought $1,000 worth of Fortrea’s shares at the IPO in June 2023 would now be looking at an investment worth $328.05.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

More News

View More
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
October 10, 2025
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
October 10, 2025
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
October 10, 2025
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
October 10, 2025
Via MarketBeat
Tickers DKNG
Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom
October 10, 2025
Via MarketBeat
Tickers BUD STZ
Recent Quotes
View More
Symbol Price Change (%)
GOOG  237.49
-4.72 (-1.95%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap